

Table SI. Effects of derma-membrane system (DMS)-based lotion with (group 2) and without (group 1) N-palmitoylethanolamine (PEA) on dry skin, sensory symptoms and quality of life

	Group 1				Group 2				<i>p</i> (visit) ^a	<i>p</i> (group) ^b
	Mean	SD	95% CI	<i>n</i>	Mean	SD	95% CI	<i>n</i>		
Pruritus VAS, assessed at study visits (LOCF analysis)										
V1 ^c	6.0	1.9	5.5–6.5	51	6.3	1.9	5.8–6.9	48		
V2	5.4	2.2	4.8–6.0	51	5.2	3.0	4.4–6.1	48	0.001	0.343
Pruritus VAS <7 at visit 1, assessed at study visits (PP)										
V1 ^c	5.1	0.9	4.7–5.4	25	5.0	0.9	4.7–5.4	25		
V2	4.9	1.8	4.1–5.7	25	4.5	2.7	3.3–5.8	25	0.250	0.512
Pruritus VAS ≥7 at visit 1, assessed at study visits (PP)*										
V1 ^c	8.1	1.3	7.4–8.7	15	8.6	1.2	7.9–9.3	16		
V2	6.2	2.8	4.7–7.8	15	6.3	3.6	4.3–8.2	16	0.001	0.709
Pruritus VRS (PP analysis)										
V1 ^c	3.8	0.8	3.6–4.1	39	3.8	0.9	3.5–4.1	40		
V2	3.7	1.0	3.3–4.0	39	3.6	1.2	3.2–4.0	40	0.223	0.937
V1 ^c	3.8	0.8	3.5–4.1	33	3.8	0.9	3.5–4.2	25		
V3	3.3	1.1	2.9–3.7	33	3.2	1.4	2.6–3.8	25	0.003	0.736
Pruritus percentage score, mean values										
V2	24.2	29.3	14.9–33.6	40	30.1	29.8	20.7–39.5	41	0.378	
V3	22.4	30.5	11.0–33.1	30	28.6	35.9	12.7–44.5	22	0.505	
DLQI: quality of life (LOCF analysis)										
V1	10.1	7.4	8.2–12.1	51	8.4	6.7	6.5–10.4	47	<0.001	0.690
V2	7.7	6.1	6.0–9.4	51	6.4	5.8	4.7–8.1	47		
Skin roughness (LOCF analysis)										
V1 ^c	2.1	1.1	1.8–2.5	50	2.2	1.4	1.8–2.6	48		
V2	2.2	1.1	1.9–2.5	50	1.9	1.2	1.6–2.3	48	0.266	0.093
Scaling (per protocol analysis)										
V1 ^c	2.0	1.1	1.7–2.4	36	2.0	1.3	1.6–2.4	38		
V2	1.9	1.0	1.6–2.2	36	1.7	1.2	1.3–2.1	38	0.118	0.569
V1 ^c	2.0	1.1	1.6–2.4	30	1.7	1.0	1.3–2.1	24		
V3	1.9	1.0	1.5–2.3	30	1.5	0.9	1.2–1.9	24	0.344	0.812
Skin tightness (LOCF analysis)										
V1 ^c	2.2	1.1	1.9–2.5	50	2.1	1.4	1.7–2.5	48		
V2	2.2	1.1	1.9–2.5	50	2.2	1.4	1.8–2.6	48	0.352	0.631
Stinging VRS (per protocol analysis)										
V1 ^c	1.9	1.0	1.6–2.3	35	2.1	1.4	1.7–2.6	39		
V2	2.5	1.2	2.1–3.0	35	2.1	1.4	1.7–2.6	39	0.037	0.024
V1 ^c	1.9	1.0	1.6–2.3	31	2.4	1.3	1.8–2.9	24		
V3	2.3	1.3	1.8–2.8	31	2.1	1.6	1.4–2.8	24	0.791	0.131
Stinging VRS (LOCF analysis)										
V1 ^c	2.1	1.2	1.8–2.5	50	2.2	1.4	1.8–2.6	48		
V2	2.5	1.2	2.2–2.9	50	2.2	1.4	1.8–2.6	48	0.092	0.062
Prurigo score (LOCF analysis)*										
V1	2.9	2.3	1.8–4.1	19	2.5	1.7	1.5–3.5	14		
V2	2.4	2.2	1.3–3.4	19	2.1	1.4	1.2–2.9	14	0.010	0.833

^aSignificant difference between mean of V1 and the respective visit without differentiating for groups. ^bSignificant difference between the 2 groups in the change of mean values from V1 to respective visit. ^cV1 values refer to patients with valid values at both visits, compared in the respective test.

*The Kolmogorov-Smirnov test demonstrated significant difference when tested for normal distribution; thus, these results should be interpreted with caution.

SD: standard deviation; 95% CI: 95% confidence interval; VAS: visual analogue scale; LOCF: last-observation-carried-forward; VRS: verbal rating scale; V1: onset week; V2: after 2 weeks; V3: end of treatment; PP: per protocol; DLQI: Dermatology Life Quality Index.